Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in good shape sufficient to tolerate FCR therapy, should be great candidates for that latter, with the profit being that this procedure might be completed in 6 months whilst ibrutinib need to be taken indefinitely. This selection could be https://edmundf455eyq6.jasperwiki.com/user